# Beijing GenomePrecision Technology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/beijing-genomeprecision-technology-co

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: www.genomeprecision.com
- Total disclosed funding: $20M
- Latest round: Series C (Apr 19, 2021)
- Investors on record: 16

## About

Beijing GenomePrecision Technology Co., Ltd. is a molecular diagnostics company based in Beijing, China, focusing on precision medicine through advanced diagnostic technologies.Founded in 2015 and headquartered in Beijing, China, Beijing GenomePrecision Technology Co., Ltd. specializes in molecular diagnostics. The CEO and founder, Feng Ye, has a history of involvement in biotechnology enterprises. The company has successfully completed 7 deals, including a Series C funding round in April 2021, raising CNY 35 million from a mix of new and returning investors, which included Galaxy Yuanhui Investment and Juren Capital.Beijing GenomePrecision Technology Co., Ltd. specializes in molecular diagnostics, including areas such as hematological oncology and tumor immunotherapy. Their offerings include advanced diagnostic products leveraging fluorescent quantitative PCR, Sanger sequencing, and next-generation sequencing, aimed at healthcare institutions and laboratories to improve diagnostic accuracy across various medical fields.The company's business model operates through B2B transactions with healthcare providers, hospitals, and research institutions for specialized molecular diagnostic services. Transactions typically involve sales of diagnostic tests and potential subscription-based partnerships, reflecting the specialized nature of their products, particularly in hematology and oncology diagnostics.In April 2021, Beijing GenomePrecision Technology Co., Ltd. secured CNY 35 million in Series C funding to support its growth initiatives. The company plans to expand its product line and is exploring new markets for its diagnostic technologies, with a focus on specific regions yet to be disclosed. Recent funding will be allocated toward developing new products and potentially entering international markets, enhancing their capacity to address clinical demands in precision medicine.

## Funding rounds

- Series C, Apr 19, 2021, $5.4M — Oriental Fortune Capital, Juren Capital, Sunland Capital, Guiyang Venture Capital, Zhongguancun Co-Innovative Fund Management, Galaxy Yuanhui Investment
- Series B, Feb 18, 2019, $15M — China Growth Capital, Juren Capital, E-Town International Industrial Investment, Sigma Square Capital, Dynamic Capital
- Series C, Jun 6, 2017 — In Capital, MED-FINE Capital
- Series B, Aug 12, 2016 — Grand Yangtze Capital
- Series A, May 30, 2016 — Oriental Fortune Capital, TEDA Venture Capital, Juren Capital, Addor Capital, MED-FINE Capital, Hangzhou Miyin Investment Management

## Investors

- Oriental Fortune Capital (https://capitalatlas.ai/funds/oriental-fortune-capital) — Series A, Series C
- TEDA Venture Capital (https://capitalatlas.ai/funds/teda-venture-capital) — Series A
- Juren Capital (https://capitalatlas.ai/funds/juren-capital) — Series A, Series B, Series C
- Addor Capital (https://capitalatlas.ai/funds/addor-capital) — Series A
- MED-FINE Capital (https://capitalatlas.ai/funds/med-fine-capital) — Series A, Series C
- Hangzhou Miyin Investment Management — Series A
- Grand Yangtze Capital (https://capitalatlas.ai/funds/grand-yangtze-capital) — Series B
- In Capital — Series C
- China Growth Capital (https://capitalatlas.ai/funds/china-growth-capital) — Series B
- E-Town International Industrial Investment (https://capitalatlas.ai/funds/e-town-international-industrial-investment) — Series B
- Sigma Square Capital (https://capitalatlas.ai/funds/sigma-square-capital) — Series B
- Dynamic Capital (https://capitalatlas.ai/funds/dynamic-capital) — Series B
- Sunland Capital — Series C
- Guiyang Venture Capital (https://capitalatlas.ai/funds/guiyang-venture-capital) — Series C
- Zhongguancun Co-Innovative Fund Management (https://capitalatlas.ai/funds/zhongguancun-co-innovative-fund-management) — Series C
- Galaxy Yuanhui Investment — Series C